Needham Upside Case: Strong Ulixacaltamide Outlook and 2026 Catalyst Stack Drive Praxis Buy Thesis

In a report released today, Ami Fadia from Needham maintained a Buy rating on Praxis Precision Medicines, with a price target of $510.00.

Ami Fadia gave his rating based on several factors highlighted in the updated Needham analysis of Praxis Precision Medicines.
Fadia points to an expanded physician survey indicating stronger long-term demand for ulixacaltamide, prompting a higher 2035 sales outlook and justifying the new price target. She underscores the therapy’s 65% probability of approval anchored in robust mITT data, meaningful unmet need, and Breakthrough Therapy Designation, while acknowledging the possibility of an advisory committee review. Praxis is viewed as nearing a pivotal transition into commercialization, with dual NDA submissions expected in early 2026 for ulixacaltamide and relutrigine. The estimated $4.8B peak sales for ulixacaltamide alone signal substantial upside relative to the current market capitalization. Further, the 2026 catalyst lineup—POWER1 data for vormatrigine in the first half and EMBRAVE3 results for elsunersen later in the year—adds multiple opportunities for value creation and cross-program readthroughs.

In another report released on February 2, H.C. Wainwright also maintained a Buy rating on the stock with a $1,245.00 price target.